The fact that trials have shown clearance of amyloid β deposits in the brains of AD subjects without impact on either clinical disease progression or progression of tau aggregation pathology [20] indicates that while amyloid pathology exists in AD brains, it may not be the primary driver of sporadic AD. This evidence concerns the gene MAPT and Alzheimer disease.